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Italiano per lo Studio della Streptockinaei nell’lnfa~to 
fGISS1) I year folios-uo rewrt (I). tru!v wtil’ied 4rher bv 
the facts or by t:te r&d&r of prac&! This medical 
prooooocement is magnified by our press, +vhich mR&es 
ommire into established fact. Thus. the IYell xrert Jounm/ 
editorializes about :ecomhinaot issue plasmino~n activator 
frt-PA). its manuiacturer and the failure until recentlv of Ihe 
&xl and Drug Administration (FDA) to approve this agent 
for genera! use (2). Thmmbolysis is in the publie eye ati is 
in public and perhaps “legal” demand. Tk?:s medical. 
commercial and media forces make practice more difficult 
than ever. 
We must examine the strategies nnderlyiq throinbolysic 
to provide, at lew as of this writing. a framework for 
selection of this therapy. Before doing this. we mtnt recog- 
size that the best regime has not yet been dc:med. Thr 
agents are numerow.: stre?totxwe. acylated rtreptokinxe, 
t-PA. uroki+ase and others And the amxcviatc dacs, 
duration of dosag> and combination of the s&al agents 
have yet tote defined. Ncvanhe’ess. most oftbese drugs are 
qproved by the FDA, and there will be ciamor for their use. 
Tke first steP is to weigh the evidence for heneft a@sn the 
risk of harm. 
Benefits and Risks of TIarombatytic Therapy 
Table I depicts the benefits and risks as sceo in everyday 
practice. First, one ZIIUEL assess the risk of the disease 
against that of therapy, and then the element of time from 
onset of symptoms to opportunity to S;ve tkerapy. Con- 
versely, certain factors pose. as of now, certmn risks rbzt & only patients with a fir.0 infarct whobenefited 114.5 
versus 17.3% mortality rate). Patients sustaining a second 
infarct reaped no benefit. Moreover. the site of the infarct is 
important. Most trials. including the GISSI. state that sor- 
viva1 is improved by tbrombolysis ii the infarct is anterior or 
located in more than one vessel. buI there is no impmvemenr 
if the infarct is inferior. Paradoxically, the Intravenous 
Strep~okinaae in Acute Myowdial Mar&n (ISAM) trial 
(4). which overall showed ao significant difference in in- 
did note a better.4 year outcome on thmmbolytic 
patients with an inferior infarct than in those with an anterior 
iniarct. The ClSSl trial highl;ghted one disturbing feature in 
the electrocardiographic (ECG) infarct pattan. When ST 
segment depression was the dominant pattern. mortality was 
much greater than in the overall study. Furthermore. mar- 
talky in the streptokinase group with this pattern far ex- 
ceeded tbat in the control group (34 versus 24%), thus 
suggesting that streptokinase should not be riven in this 
ECG setting. 
F5icacy. The Western Wcshingron Study. In this study 
(51, among patients who had successful reperfuaion. 2.5% 
died before the end of 1 year whereas 23.1% with partial 
repafurion and 14.6% with no petfusion died. Indeed, a 
large number of studies have demonstrated that arterial 
Figure 1. Th GlSSl repon &wrd improved survival with tbrom- 
My& therapy. pardeularty iz the soup trcat:d within 3 h of tic 
onset of pain. Dotted line = contml: solid line = streptokinase. 
Reprinted with permission from The Lmcc! (I). 
tricuku ejection fraction itiuettce survival after myocardial 
infarction is difficult to recomile with the tinding that the 
effects of tbrombolytic therapy do not seem 10 improve 
survival further after the immediate in-hospital phase of 
infarction was concluded. 
paancy after thrombolytic therapy varies fmm as low as 40 Bleedin& One ofthe major complications of thmmbolytic 
to LP hiph 26 86%. Initially, R-PA ns considered mare therapy, bleeding, is dependent on many factors. Table 2 
&ective than streptokinase. br:: subsequent studies (6) have demonstrates that bleeding incidence with CPA increased 
not borne out such adistinction. There is some evidence that with dose even as dose increased frequency of recanaliza- 
patency is both dose and time related (7), with t-PA having tion. Bleeding generally occurred at sites of vascular access, 
an advantage the longer the time afier onset oiinlarction. although gastrointestinal nd intracranial bleeding were seen 
The variable and unpredicmbk oc~urrmc~ of reperfrrsion as well, the latter at an incidence rate of 0.5 to 1.5% (7.8). 
(and early reocclusionj may accou112 forrhe nkwd o,,,cmm=. Many of the episodes of intracranial bleeding in different 
Witness the ditTerence in t year mollality between patients series occurred in patienls with known prior hypeltension 
exhibiting rewfusion versus patients in whom reperfusion (contmUed or not) and often with diabetes mellitus. No 
was not achieved or was achieved only partially (98 versus 
83%. respectively) in the Western Washington study. 
distinction between the several thmmbolytic agents in ws- 
ing hemorrhage has been reported. Of additional concern has 
These issues notwithstanding, there is firm evidence that been the high incidence of transfusion required (Table 2) 
timely thrombolysis will preserve ventricular myocardial with the attendant 8 to IS% risk of hepatitis or other viral 
mass and function. Knowing that infarct size and left ven- disorder in recipients. 
tion to thwan these ischcmic events, which were far in 
excess of what would have been expected for a simiiar group 
of traditionally managed pattents. 
F@.re 2. When the GtSSt ruwivat data are shown an a lull ECB,. 
graph, the difference in t year survival and cumulative ~urvi~at 
between treated and untreated groups is not PC emphn!% except I 
the subgroup treated within one hour. 
Reocchaiw ad remmellt Qhemk eventp. Acute rem- 
elusion occurs in 19% of patients with successful reperfu- 
sion. Not only must this be usderstcnd as a Measure of 
sueeessorfailureoftherapy,hut i soverall significancemust 
bc grasped. The ttalural histoty of the acute coronary artery 
lesion has been fundamentally changed by lysis of the 
tbrombus. There are still a denuded intimal or even medial 
rwtttre, localized intramural hemorrhage and, thus. instabil- 
ity of the athemsclerotic plaque (9). This plaqwthromhus 
lesion is NW unstable and unresolved, with recurring throm- 
bvtic occlusion and patency and with variable tissue pafu- 
sion. The pwtlysis ecmrse now resembles the course of a 
non-Q wave myocardial infawion, which often has the same 
coronary artery pathology. As a result, much like a non-Q 
wave myocardial infa&n, there oflen folkws recurrent 
infarction and frequent induction of an& pectoris, whether 
or not it was prevent bcforc. This pilttem eventuate3 in 
coronary angtoptasty or bypass surgery, or both in 30 to 
40% of patients. Pooled data from IS trials (IO) indicated that 
nonfatal infarction occurred in 45% of patients after !hram- 
b&is and in 1% of the placebo group. In some instances, 
IO to 15% of p&ems sustained an infarction. Likewise. 
Karen et al. (Ii) reported a high rate of postlysis complica- 
tions in a group of patients who received very early admin- 
istration (within 1.~ h) ofstreptokinase by way ofambulance 
attd emergency roan protocol. Despite prompt reperfusion 
therapy, 75% of their patients had. within 3 months. some 
cardiovascular manifestation. such as anpina, hean failure, 
myocardial reinfarction or an abnormal stress test. Ironi- 
cally, these investigators argued for nwre invasive interven- 
Recommendations 
To summarize. maximal benefit occurs in the mtient who 
is seen within the first 3 h of symptoms. who is undergoing a
Brst infarc:ion, whore infucr is anterioi oi xattitiple iil site 
and putatively large and who has were left ventricular 
dysfunction ttne tatter is usuaity a sign of a major re&at 
perfusion detictt). Cardiogenic shock. owing to its >85% 
mortality rate with sta&rd therapy. shou!d be treated by 
thmmbolvsis if direct arteioolastv is unavailable (12). These 
principks can be further-&&d by earlier administration 
of therapy, use of rapidly acting therapy and inhibition of 
postthmmbolytic thrombogenic reb-und (13). 
There is also rhe human elemenr. which governs rke 
errrcial window of lime. The patient must be informed, aware 
and willing to react al;d not deny the nature of a symptom. 
The physician. too. must be alert and responsive, and not 
secessariPi just $w an antacid ci nitroglycerin and ask for a 
repon in a couple of hours or, worse still, “in the morning.” 
And finally. the system must work. The trampon mecha- 
nism and staff mvalved must be prepared: there must be an 
institutional protocol ready with the hospital staff we!1 ap 
prised when palients reach the emergency rcan so that a 
formal plan goes into &cl involving Ihe decision for and 
application of thrombnlytic therapy. 
Mlsiming tbt risk (Table 1). How can risk best be 
minimized? The Rrst step indicated by the dam is an age 
cutoff at 65 to 70 years. Hypertension teems a particularly 
significant risk factor, especially in promoting the likelilwi 
of intracranial and other bleeding. Some suggest hat even 
moderate levels of hypertension enhance risk. If good con- 
trol of blood pressure cannot be documented. perhaps 
thrombotytic therapy should be foregone. Mar cerebmva- 
scular accident and prior b!eeding site or iinorder are well 
recognized contraindications. Possibly longstanding diabe- 
tes with arteriopathy may enhance risk and thus constitute a
r&&e cnntniwtication. 
Furlher ways IO reduce risk ore 10 avoid anerioi code- 
rerizarions. unless essential, so as to reduce vascular bleed- 
ing opportunities and perhaps to delay heptin and aspirin 
use during the acute phase of thrombolysir. Whether this 
will adversely affect coronary artery patency is unclear at 
prese”,. 
predicting or reeogotzing sueeezsfot re~erfuston. As ex- 
peeled. there are many unresolved issues concerning throm- 
bolytic reperfusion. Having just stated that it is the large 
infarct that benefits from reperfusion, how do we determine 
this at the onset of ischemia? The initial ECG findings does 
not always show Q wves and abnormal repolarization 
findings in a large number of leads suggestive of a large 
infarction. nor do serum enzyme levels help early on. Then 
bow do we recognize if reperfusian or rewclusion has 
occurred after therapy? No tests to date shon of angiwa- 
phy provide us thi; information for future planning (141. 
Opaing the ancry by thmmbolysis is nor only unpredict- 
able. occurring. in 50 to 75% of patienrs. but ihe degree oi 
resulting a&al patency and perfwion is unpredictable. 
This will depend in part on Low much of the original 
occlusion war due to plaque ruptw with intmluminal pro- 
trosion and how much was due to overlying or propagated 
thrombus. The local conditions of the vessel wall, flow rate 
and reaction to tibrinolysis all govern the rate of reocclusion, 
estimated at about 20%. 
Posttbmmbolytie management. The subsequent course 
after hospitalization depends on the abrbpt change in the 
nature of the coronary anety lesion, which leads to ih- 
creased ischcmic events. Consequeotly, interventions uch 
as repeat cardiac catheterization, angioplasty and bypass 
surgery will be required in up to 5% of all patients. The 
attendant risks and costs are obvious and tend to mitigate the 
benefits of repelfusion. 
favored betbhlofker use [Table 3). These arc precisely the 
key contraindications to thrombalytic therapy. Conversely, 
major hemodyaamic failure is best approached through 
repvfusion techniques. 
How do these aents comoore? With thrombolvrir. about 
2. perhaps 3 liw”are saved per IW treated p&its (17) 
(Table 4); however, with bera-blockade, titan 0.7s to I life 
is saved per IO0 treated patients. As with tbrombolysis, the 
salvage with beta-blockade is greater the earlier the treat- 
ment is begun. 
In comparison. patients presenting with ST segment 
depression did poorly with streptokinase (I), whereas no 
such subgroup has been reported (IS) in Patients with 
beta-blockade. In the subgroup with non-Q wave infarction, 
the MtAMt trial did repan (18) an insignificantly higher 
mortality rate among patients treated with mctoprolol than 
among &trol patients. Although thrombolytic therapy in- 
creases the risk of reinfarction, conti:. :d beta-blocker ther- 
apy reduce8 this risk. 
Eli@lity for tbrrmbdyttc vent bda&cker lbempy. A 
crucial factor in examir.ing a therapy is its applicability to B 
given disease. Hjalmarson (IS) estimated that about 80?& of 
all oatients with acute mvocardial infarction are eligible for 
tre&ent with beta.adr&rgic blockade. In co&& the 
Comparison of Thrombolytic Therapy percent of patients eligible for thrombolysis has been re- 
It is useful to compare thrombolytic therapy with intra- 
poned to be as high as 35% (GISSI-I) (19) and as low as 9% 
(Fig. 3) (20). The latte, repon was based oil case findings for 
woous beta-adrenergic blocker therapy For acme myocar- B randomized trial. One hundred three uatients 126%) failed 
dial infarction. The latter is considered a less patent and to meet criteria ior acute myocardiil i&rction. 157 (3%) 
direct approach to the acute infarct. In the Metopropolol in arrived outside the therapeutic time window. 42 (10%) were 
Acute Myocardial infarction (MIAMI) trial. no difference in 
survival of the control and treated groups was reported (IS) 
above age 70,45 (II%) had a disqualifying medical disorder 
although. as in the ISAM trisl of streptokinare (8). mortality 
and 5% were disqualified for other rewms. The difference in 
in Ihe control wow was unexoectedlv low 14.7%). In a 
applicability of therapy between rhmmbolysis and beta- 
subgroup anal& tijalmarson (in and &son (I6)and their 
coworkers defined a cohort of patients who were clearly at Table 4. tmpact an D~tcome ofPatient Eligibility for. and 
high risk and who had an increase in post myocardial 
EBieacy of, 8trcptokin.a Verses Beta-Blockode Therapy 
- 
infarction survival oo beta-adrenergic blocker therapy. Cer- x8 patisnu have an MI 
tain features of risk. such as advanced age. hypenensiue. tW @X1 arc eli&te for beta.btcekade. 1.6 ,,ws are raved ,litM treaml, 
prior myocardial infarction and possibly diabetes. actually JO (25%) are otidbla far thmmbolyso. I life is wed IUIW luratedl 
bhxkade will a&t the “power” of each to swc lives. To 
illustrate, assume 200 patients present with myocardial in- 
farction; I&l would be eligible for beta-blockade. If I life is 
saved per IO0 patients Ire&d, I .6 lives will be saved in the 
original cohort of 200 patients (Table 4). Let us assume a 
generous eligibility factor for thrombolysis of 2570; then if 2 
lives are saved per lo0 patients, I life is saved in the origiinal 
cohort of 200. Therefore, applicability as well as efficacy will 
govern how mu& pain in s&val is made. A less efficacious 
agent mw generally applicable may improve survivorship 
considerably. 
Is Ihere odvanlage lo combined betu-udrnwrgic blocker 
therapy wirh rhrombolysis? This is currently undergoing 
clinical trial. In [heir trial of streptokinase, White et al. (6) 
had a subset of patients who recvived propran.-‘~1. Althouph 
the study was not designed 10 test any additive &feet of the 
two therapies, proprmwlol caused no adwse rcnponse. 
Role of Angiqhsty 
The role of angioplasty as pan of the treatment algorithm 
is a180 under investigation. Immediate angioplasty seems to 
confer no benefit and may lead to early reocclusion. possibly 
owing to exacerbalion of preexisting coronary artery dam- 
age. Cardiogenic shock is probably the one exception. 
Emergency angioplasty without prior thmmbolysis may 
likely be the appropriate therapy for this almost always fatal 
complication of myocardial infarction (21). Elective angiw 
plasty may or may not be a useful adjunct& therapy and is 
under funher study. 
Conclusions 
A small overall gain has been made wilh thmmbolynin. 
which can benefit a small subset of patients with acute 
myocardial infarction, provided thar buih the imrnediatc and 
the long-term risk: are carefully assessed. This slatenent 
should be compared with an editorial in the WaM Strerr 
The private world of medicine has “gone public.” Nev- 
enheless. the judgment of the tbaughlful physiclan must 
prevai! 3” the fact of premature. unsc~entitic endorsement of 
therapy 10 do what is really besi for the patient. 
Addendum 
Since preparation of this editorial. the ISIS-2 trial was 
reported I” prelimirnry form at the Annual Meeting of the 
American College of Cardiology (March 27 to 31. 1988) in 
Atlanta. Georgia. 
In a four-armed randomized trial, intravenous rlreptaki- 
nave reduced 5 week mortalily from acute myocardial infarc- 
tion from I I .7 (placebo) 10 8.970. lo another arm of the uial. 
I60 mg aspirin alone given as antiplatelet herapy praluced 
a conmarable reduction in mortalitv rate from I I .4 to 9.2%. 
The &bmed mterventions prod&d aq additive zduction 
in risk from 12.8 to 7.8%. In contrast to prior studier. 
eilicacy was qualitatively unti~cted by time lo therapy, age 
OF prior history of or site of myocardial infarction. 
A rhrombolylic-platelet inhibitor treatment algorithm 
may well broaden applicability as well as enhance fficacy in 
the managemen! of acute myocardial infarction. 
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